Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734(TM)) in Participants With Severe Coronavirus Disease (COVID-19)
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
GS-US-540-5773: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Severe COVID-19
- ClinicalTrials.gov Identifier: NCT04292899
- Protocol Number: 2020C000247
- Principal Investigator: Kathryn Stephenson
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required